With LabCorp unleashing a series of predictive cancer diagnostic tests focused on BRCA mutations, a market once dominated by one major player is now crowded with least 7 rivals. Such is the aftermath of a U.S. Supreme Court decision over the summer that helped open the door to competition involving BRCA-related diagnostic tests.
No one ever climbed the industry ladder without getting some help along the way. And for women, including many of the accomplished top performers in this group, that can be especially important. Maybe it was an encouraging nudge for a bright young scientist or a willing mentor for a rising company player--but virtually everyone in this year's group of top women in biotech benefited from a higher-up's helping hand.
Now, these women are re-gifting that upward boost to the next generation of leaders. Some are actively involved in nonprofit groups aiming to inspire women in business. Others single out promising younger women who might benefit from their guidance and experienced counsel.
This year's Class of 2013 includes entrepreneurs running biotechs, raising cash and advancing new drugs in the clinic. Read the full report >>
"The areas most interesting are companion diagnostics with specific forms of therapy," said Goldfischer, a managing director and investment partner with Bay City Capital. "You have seen a lot of novel cancer agents being developed against specific targets, with the thought of companion diagnostics to be able to identify specific targets and responsiveness of patients--those areas are really interesting to do and [include] quite novel, innovative companies."
POPULAR COMMENT THREADS
Biodesix grabbed $8.3 million in Series E financing to help boost sales and marketing efforts for its personalized medicine-focused lung cancer test.
Researchers at the University of Cambridge in the U.K. and colleagues spotted a new cancer gene that will enable a single test that screens for most chronic blood cancers, The Times of India reported.
A new $40 million Series E round will help get the word out about Invitae's gene-sequencing tests, which are built to help physicians and genetic counselors screen for almost innumerable genetic disorders, and fuel the ramp-up of sales and new development.
Foundation Medicine is touting some promising new data highlighting the utility of its signature diagnostic technology for blood cancers, news that will help the newly public Massachusetts startup maintain development and commercial momentum.
Hologic now has a fresh CEO and two added board members, thanks to the machinations of activist investor Carl Icahn. But the new leader of the Massachusetts company known for women-focused diagnostic medical imaging and surgical products insists growth is a much bigger priority over a sale, at least for now.
DioGenix is expanding the scope of a crucial clinical trial for a multiple sclerosis genetic test that could drastically reduce misdiagnosis of the degenerative disease. President and CEO Larry Tiffany told FierceDiagnostics that $3.2 million in new financing will help bring what has arguably become the largest trial of its kind in MS to completion through 2014.
From Our Sister Sites
ImmunoCellular Therapeutics put out the word Wednesday afternoon that its dendritic cell-based vaccine for brain cancer flunked the key overall survival test in Phase II, news that swiftly wiped out more than half of the small biotech's market cap as shares instantly cratered.
Prothena's PRX002, a preclinical treatment targeting Parkinson's disease, is at the heart of a deal with Swiss pharma giant Roche, worth up to $600 million plus 30% of U.S. profits to the Irish biotech.